Halozyme Therapeutics (HALO) Equity Ratio (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Equity Ratio data on file, last reported at 0.08 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.08, down 62.57% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.08 (down 62.57% YoY), and the FY2025 annual result was 0.02, down 89.04% from the prior year.
• Equity Ratio advanced to 0.08 in Q1 2026 per HALO's latest filing, from 0.02 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.23 in Q3 2025 and troughed at 0.02 in Q4 2025.
• A 5-year average of 0.13 and a median of 0.13 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio soared 264.64% in 2024, then tumbled 89.04% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.09 in 2022, then sank by 47.56% to 0.05 in 2023, then soared by 264.64% to 0.18 in 2024, then slumped by 89.04% to 0.02 in 2025, then soared by 325.13% to 0.08 in 2026.
• Business Quant data shows HALO's Equity Ratio at 0.08 in Q1 2026, 0.02 in Q4 2025, and 0.23 in Q3 2025.